StockNews.com Begins Coverage on Minerva Neurosciences (NASDAQ:NERV)

Stock analysts at StockNews.com started coverage on shares of Minerva Neurosciences (NASDAQ:NERV) in a report issued on Monday. The firm set a “sell” rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright reduced their price objective on shares of Minerva Neurosciences from $7.00 to $5.00 and set a “neutral” rating for the company in a research report on Wednesday, August 7th.

Minerva Neurosciences Stock Performance

NERV stock opened at $2.70 on Monday. Minerva Neurosciences has a one year low of $2.26 and a one year high of $13.49. The firm’s fifty day moving average is $2.85 and its 200 day moving average is $2.80. The firm has a market cap of $18.88 million, a PE ratio of -0.60 and a beta of 0.14.

Minerva Neurosciences (NASDAQ:NERV) last posted its earnings results on Tuesday, August 6th. The biopharmaceutical company reported ($1.09) EPS for the quarter, missing analysts’ consensus estimates of ($0.97) by ($0.12). Research analysts predict that Minerva Neurosciences will post -2.26 earnings per share for the current fiscal year.

About Minerva Neurosciences

Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders.